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ABSTRACT: 
Background: Follicular lymphoma (FL) is the most common subtype of indolent lymphoma. FL 
is  still  considered  to  be  an  incurable  disease  and  palliation  of  symptoms  is  an  acceptable 
approach  to  the  expected  pattern  of  repeated  relapses  due  to  developing  resistance  to 
chemotherapy  agents.  Apurinic/apyrimidinic  endonuclease/redox  factor-1  (APE1/Ref-1)  is  a 
multifunctional protein involved in DNA base excision repair (BER) of oxidative DNA damage 
and in redox regulation of a number of transcription factors. It was observed that cytoplasmic 
APE1  induced  COX-2  expression  through  NF-κB  activation.  It  has  been  shown  that 
chemopreventive  agents  potentiate  the  efficacy  of  chemotherapy  through  the  regulation  of 
multiple signaling pathways, including NF-κB, c-Myc, cyclooxygenase-2, apoptosis, and others, 
suggesting a multitargeted nature of chemopreventive agents. We hypothesized that curcumin, a 
polyphenolic antioxidant derived from the spice turmeric, and epigallocatechin gallate (EGCG) 
from green tea would
 potentiate the effect of chemotherapy in B-cell lymphoma. 
 
Objective: We examined the role of human apurinic/apyrimidinic endonuclease 1 (APE1) in 
resistance and prognosis in patients with FL. Our major objective was to update the safety and 
efficacy  results  of  the  antitumor  effect  of  combination  of  curcumin  and  EGCG  therapy  in 
relapsed or resistant indolent or transformed non-Hodgkin follicular lymphoma patients and their 
peripheral blood mononuclear cells (PBMCs) compared with healthy donors’ controls.  
 
Methods: Thirty patients with FL with over-expression of constitutive active NF-κB in their 
PBMCs  received  regular  CHOP  and  consumed  capsules  compatible  with  curcumin  doses 
between 0.9 and 5.4 g daily for up to 9 months and 9.0 g/day green tea whole extract "1000 mg 
tablets of green tea whole extract containing 200 mg EGCG. We designed a dose-escalation Functional Foods in Health and Disease 2011, 1(12):525-544                                                        Page 526 of 544 
 
 
study to explore the efficacy of CHOP in combination with curcumin and the green tea extract 
epigallocatechin-3 gallate (EGCG) on the viability of patients’ peripheral blood mononuclear 
cells (PBMCs) lymphocytes.   
 
Results: Treatment of patients with the combination of curcumin and EGCG, significantly lower 
cytoplasmic APE1 and the levels of the transcription factor were lower than those predicted from 
the effects of the CHOP agents (cyclophosphamide, doxorubicin, vincristine, and prednisone) 
alone, especially with a blunting of the remarkable increases in NF- κB activation induced by 
CHOP. Eighteen of the patients had a CR (18/30), and twelve patients had PR (12/30) within 9 
month treatment and followed up to 12 months. They remain disease-free a mean of 8.6 y (range, 
7.9–9.2 y) after this combination therapy. 
 
Conclusion:  Optimal  patient  benefit  might  be  obtained  in  follicular  lymphoma  when 
administering curcumin up-front in combination with chemotherapy and EGCG treatment. The 
combination of curcumin with EGCG resulted in a synergistic antitumor activity and that with 
CHOP  agents  in  additivity  or  sub-additivity,  down-regulated  the  expression  of  all  NF-κB 
regulated gene products, leading to the suppression of angiogenesis, metastasis and entering in 
complete remission as indicated by β2-microglobulin and lactate dehydrogenase (LDH) levels.  
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INTRODUCTION: 
NHL  is  an  increasing  problem,  now  being  the  fifth  most  common  malignancy  in  Egypt. 
Incidence have risen with age, due to the population agesing NHL has become increasingly 
common. The reason for the increase is not clear, but attention has focused on environmental 
factors.  It is interesting to note that the Egyptians high rates of NHL among other populations 
may  be  due  to  the  adverse  environmental  exposure  and  pollution  in  Egypt  [1-2].  Improved 
understanding of the biology of normal B-cell development, and that B-cell NHL correspond to 
specific stages of normal B-cell development, has led to a more rational classification of B-cell 
malignancy [3]. About 1/3 of NHL have a follicular growth pattern, reminiscent of normal lymph 
node architecture, and these generally have an indolent clinical course, or low-grade histology 
[4]. The NHL Classification Project has defined the clinical features of the most common NHLs, 
which are (in order of frequency) diffuse large B-cell lymphoma (DLBCL) (31%), follicular 
lymphoma (FL) (22%), which are the most common types of B-cell lymphomas [5]. Currently, 
medical  treatment  for  lymphoma  revolves  around  the  following  therapies:  chemotherapy, 
radiation and monoclonal antibodies (rituximab) [6, 7]. The standard chemotherapy regimen for 
NHL, known as CHOP, combines four agents: cyclophosphamide, doxorubicin, vincristine, and 
prednisone [8-9], but the disease is  considered incurable with current therapeutic options. A 
clinical course is usually a series of remissions and relapses, with different treatments used for 
each relapse. Thus, new targeted treatments are vital  to improving the clinical outcomes for 
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A  better  understanding  of  critical  pathways  and  molecular  mechanisms  involved  in  B-cell 
lymphoma development, progression, and resistance to traditional therapy is critical. Reduction–
oxidation  (redox)  signaling  systems  are  emerging  as  important  targets  in  most  cancers.  AP 
endonuclease1/Redox effector factor 1 (APE1/Ref-1) is upregulated in human cancer cells and 
modulation of its redox activity blocks the proliferation and migration of cancer cells and cancer-
associated  endothelial  cells  in  vitro  [10].  Cells  have  several  antioxidant  systems  including 
enzymes and redox-sensitive molecules (Trx, APE1/Ref-1) that protect the cells from oxidative 
stress  [11].  Activation  of  APE1/Ref-1  increases  the  binding  of  oxidative  stress  regulating 
transcription factors (Hif-1, p53, Ap-1). There are many studies on the relationship between p53 
and APE1/Ref-1 [12-13]. Oxidized APE1/Ref-1 facilitates p53 DNA binding. In contrast, p53 is 
a negative regulator of APE1/Ref-1 promoter. Despite accumulating evidence for the role of 
APE1/Ref-1 in redox regulation, the underlying mechanism is poorly understood. Furthermore, it 
has been shown that redox chaperone activity of APE1/Ref-1 is critical to NF-κB-mediated gene 
expression  in  human  cells  and  is  mediated  through  its  physical  association  with  target 
transcription  factors.  Thus,  APE1/Ref-1  may  play  multiple  roles  in  an  anti-oxidative  stress 
response pathway through its different biochemical activities. These findings also provide new 
insight into the mechanism of intracellular redox regulation [14]. 
Great interest is growing in identifying pharmacological agents that are able to modulate B 
cells  and  their  microenvironment  interactions  that  impact  survival  pathways  in  the  hope  of 
identifying  potential  novel  therapies  for  treatment  of  B-cell  lymphoma.  Naturally  occurring 
compounds  are  a  potential  source  of  agents  that  could  modulate  these  survival  signals  and 
interrupt stromal nurturing. It was previously shown that the green tea extract, epigallocatechin-3 
gallate (EGCG), the most abundant catechins in green tea credited with the majority of health 
benefits  associated  with  green  tea  consumption,  inhibits  vascular  endothelial  growth  factor 
receptor activation and induces  apoptosis  in  primary CLL B  cells  [15]. This  agent  has  now 
entered clinical testing in patients with early-stage CLL [16-17].  
Another  natural  compound,  curcumin  (diferuloylmethane),  derived  from  turmeric 
(Curcuma longa), together with EGCG are pharmacologically safe agents that have been found 
to be potent suppressors of nuclear factor kappa B (NF-κB) activation and NF-κB gene products 
[18]. How these agents suppress NF-κB activation is becoming increasingly apparent. These 
inhibitors may block any one or more steps in the NF-κB signaling pathway, such as the signals 
that activate the NF-κB signaling cascade, translocation of NF-κB into the nucleus, DNA binding 
of the dimers, or interactions with the basal transcriptional machinery [19-20]. Patients with 
indolent NHL were considered a suitable population in which to test naturally dietary agents’ 
curcumin and EGCG-based therapy initially, because there is often no urgent need for therapy. 
Since natural products-based therapy might be slow to act, an indolent disease would also permit 
a safe period of observation.   
In  the  present  study,  we  evaluated  the  antitumor  effect  of  curcumin  and  EGCG  in 
combination  with  chemotherapy  on  B-cell  follicular  lymphoma  patients  and  their  peripheral 
blood mononuclear cells (PBMCs).  
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Subjects and Study design: A total of 40 subjects participated in the present study. Ten subjects 
were considered the healthy control group, and 30 subjects of the same socioeconomic level, 
aged 25-61 years, were with NHL. All subjects were diagnosed by the staff of the Faculty of 
Medicine at The Department of Internal Medicine and Hematological Diseases at Alexandria 
University. Blood was obtained from FL patients who had provided written informed consent 
under a protocol approved by   the ethics committee at Alexandria University according to the 
regulations of the ethical guidelines of the 1975 declaration of Helsinki. All B-cell NHL patients 
had a confirmed diagnosis using the International Workshop definition.  Patients in this cohort 
had not been treated before blood processing for this study within the last two years. B-cell NHL 
cells  were  isolated from heparinized venous  blood  by density  gradient  centrifugation. Blood 
samples were withdrawn from all subjects (before (zero time), after three, six, nine, and twelve 
months of treatment), by vein puncture under complete aseptic conditions. Subjects included 18 
males  and  12  females,  diagnosed  with  B-cell  NHL  at  different  stages  (I-IV),  and  with 
histological subtypes (FML). Performance status (ECOG-PS) was assessed for all participants 
before and after treatment in numerical order from zero to five.   
The extent of disease was coded according to the Ann Arbor staging
 system and assessed 
by clinical examination, the chest and abdomen
 computed tomography scan, and a bone marrow 
trephine biopsy. An analysis of prognostic factors has been performed on patients with high and 
intermediate grade non-Hodgkin's lymphoma (NHL) treated over a one-year period. Response
 to 
treatment was determined every three months of therapy, with the examinations necessary to 
verify  the  absence
  of  abnormal  findings  at  diagnosis.  Response  criteria  for  non-Hodgkin’s 
lymphoma
 proposed by the International Workshop were applied.
  
During  the  study  period,  patients  were  treated  with  either  CHOP  or  CHOP-based 
combination chemotherapy with either curcumin or curcumin and EGCG for nine months, and 
followed up to twelve months. CHOP resistance was defined as patients who had progression 
during first-line CHOP chemotherapy or relapse within six months after treatment. Patients were 
then  on  regular  visits  to  the  clinic  every  six  months  for  necessary  examinations  to  assure 
continuous remission. Blood samples were collected every three months for a one-year period. 
Attainment of complete remission (CR) was the most important predictor of overall survival; low 
serum lactate dehydrogenase (LDH), limited stage disease, and a high serum albumin were also 
independently associated with prolonged survival in multivariate analysis. 
Furthermore, the effect of the studied herbal therapy to overcome the drug resistance of 
NHL-patients to chemotherapy was estimated via the determination of Glutathione S-Transferase 
(GST) activities. (GST) plays a central role in the defence against free radicals, peroxides and a 
wide range of xenobiotics and carcinogens. Hepatic and renal function tests were determined to 
evaluate the toxicity of herbal therapy, if present. 
 
Reagents and Kits: The bFGF and VEGF kits were purchased from R & D systems-(UK). β2-m 
kit  was  purchased  from  Immunotech,  (France).  LDH  kit  was  purchased  from  Diamond 
diagnostics-(Egypt).  Green  tea  whole  extract  tablets  were  purchased  from  Techno-med  Co. 
(Egypt). Curcuminoids C
3 complex
® capsules (95%) were purchased from America's Finest, Inc. 
(USA).  The  biotinylated  oligonucleotidic  probe  and  rabbit  anti-NF-кB  antibodies  were Functional Foods in Health and Disease 2011, 1(12):525-544                                                        Page 529 of 544 
 
 
purchased from LiniLab. (Cairo, Egypt). BSA, EGTA, nonidet P-40, PMSF, protease inhibitors 
and tween-20 were purchased from Sigma Chemical Co. (USA).  
        
Nuclear Fraction Preparation: The extraction of nuclear proteins was performed according to 
Dignam et. al., 1983 [21] procedure, by lysing the red blood cells (RBCs) in 1.0 ml of cold RBCs 
lysis buffer (8 mM Tris buffer, pH 7.2 containing 141 mM NH4Cl). Briefly the samples were 
vortexed for 30 sec, then centrifuged for 1 min at 10,000-12,000 × g  and red supernatants were 
poured off. To the white/red pellets, 2.0 ml of RBCs lysis buffer were added and the tubes were 
vortexed for 2-3 sec to resuspend the pellets, then centrifuged for 30 sec at 10,000-12,000 × g. 
All fluids were drained off, and this step was repeated until pellets became white/pink. The cells 
were lysed in hypotonic buffer (10 mM HEPES buffer, pH 7.5 containing 10 mM KCl, 3 mM 
NaCl, 3 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 2 mM DTT, 2 mM PMSF, and protease 
inhibitor tablet) and on ice for 15 min. Then 0.1 volume of 10% NP-40 was added and the tubes 
were  vortexed  for  10  sec  and
  centrifuged  at  500  ×  g  for  10  min  at  4°C.  The
  supernatants 
(cytoplasmic extracts) were discarded, and the pellets were washed in
 200 µl of hypotonic buffer 
and recentrifuged. The pelleted nuclei
 were resuspended
 in 50 µl of ice-cold nuclear extract (NE) 
buffer (20 mM HEPES buffer, pH 7.5 containing 25% glycerol, 500 mM KCl, 1 mM
 MgCl2, 1% 
NP-40, 1 mM EDTA, 2 mM DTT, 2 mM PMSF, and protease inhibitor tablet), and incubated on 
ice for 20 min, with occasional mixing, then centrifuged at 14,000 × g for 15 min at 4°C. The 
resulting supernatants (nuclear proteins) were aliquoted and stored at -80°C for estimation of 
NF-кB. 
 
Treatment of PBMN Cells with Curcumin and EGCG: Cell culture: The cell culture medium 
consisted of RPMI 1640 supplemented with
 10% heat-inactivated fetal bovine serum, 10 mM 
HEPES buffer, 2
 mM L-glutamine, 50 µg of gentamicin/ml, 100 U of penicillin/ml,
 100 µg of 
streptomycin/ml, and 0.25 µg of amphotericin B/ml. PBMC
 were isolated from whole blood by 
centrifugation through Ficoll-Hypaque
 solution. PBMC isolated from whole blood were washed 
twice in RPMI 1640, and resuspended in culture medium at a concentration of 10
6/ml. Then, 
0.5 ml of cell suspension was added to wells of a 24-well
 tissue culture plate. PBMN cells were 
treated with various doses of curcumin (2.5-15 μmol/L) or EGCG (25-150 μmol/L) individually 
or  in  combination  using  a  constant  ratio  (1:10)  for  24  h.  Cells  were  harvested,  for  further 
analysis. PBMN cells were treated with DMSO, curcumin (20 μmol/L), EGCG (100 μmol/L), or 
sequentially with both drugs. For sequential treatment experiments, 1.0 × 10
6 PBMN cells/mL 
were treated with DMSO, curcumin (10 μmol/L) alone, EGCG (100 μmol/L) alone, or both 
agents for 24 h; washed; and cultured for another 24 h in media alone or with the addition of the 
second agent (EGCG or curcumin), as indicated. Cells were then harvested for further analysis. 
 
Determination of Serum LDH and S-β2microglobulin (β2-m): LDH activity was determined 
kinetically according to the recommendation of the German society of clinical chemistry (1970) 
[22]. One milliliter of a working solution [buffer/substrate reagent (10 mM CAPSO buffer, pH 
7.5 containing 10 mM phosphate and 0.6 mM pyruvate) was mixed with NADH reagent (0.18 
mM  NADH)]  was  added  to  20  µl  serum  sample  in  the  cuvette,  then  mixed  and  the  initial Functional Foods in Health and Disease 2011, 1(12):525-544                                                        Page 530 of 544 
 
 
absorbance was measured after 30 sec against air blank at 340 nm., and after 1, 2 and 3 min other 
readings were taken for the determination of the mean absorbance change per min (∆A/min), 
which multiplied by 8095 to give the LDH activity in U/L. 
Serum β2-m levels were assayed by ELISA method of Benkirane et. al. (1990) [23]. Ten 
microliters of serum sample or standards were pipetted into the appropriate wells, and 200 µl of 
enzyme  conjugate  were  added  per  well,  then  the  plate  was  incubated  for  90  min  at  room 
temperature (RT), with constant shaking. The wells were then aspirated and washed three times. 
The substrate was added, the plate was incubated 30 min at RT with constant shaking, and then 
the stopping solution was added. Finally, the plate was monitored with an ELISA reader at 405-
415 nm against substrate blank. The concentrations of serum β2-m in mg/L were estimated from 
the standard curve. 
 
NF-кB ELISA Assay: NF-кB was determined using an NF-κB enzyme linked immunosorbent 
assay (ELISA)-based transcription factor assay kit according to the manufacturer’s protocol [24]. 
The Non-Radioactive NFκB p50/p65 Transcription Factor Assay kit [TransAM
TM, Carlsbad, CA, 
USA, Catalog # 40096 (p65)] is provided in a 96-well format. During the assay, the Capture 
Probe, a double stranded biotinylated oligonucleotide containing the consensus sequence  for 
NFκB binding (5’-GGGACTTTCC-3’), is mixed with nuclear extract in the Transcription Factor 
Assay Buffer provided. When incubated together, the active form of NFκB contained in the 
nuclear  extract,  binds  to  its  consensus  sequence.  After  incubation,  the  biotinylated  double 
stranded  oligonucleotide  bound  by  active  NFκB  protein  is  immobilized  and  any  inactive, 
unbound material is washed away. The bound NFκB transcription factor subunit p65 is detected 
with specific primary antibodies, a Rabbit anti-NFκB p65. A secondary horseradish peroxidase 
(HRP)-conjugated  secondary  antibody  is  then  used  for  detection  and  provides  sensitive 
colorimetric detection that can be read in a spectrophotometric plate reader. After incubation 
with developing solution, the reaction was stopped. Finally, the absorbance at 450 nm was read 
on the ELISA microplate reader.  
  
VEGF  and  bFGF  Assays:  The  determination  of  VEGF  was  carried  out  according  to  the 
procedure of Kondo et. al. (1994) [25]  by using monoclonal antibodies specific for VEGF in a 
classical ELISA protocol. The concentrations of serum VEGF in pg/ml were estimated from the 
standard curve. Human bFGF was determined using a competitive enzyme immunoassay (EIA) 
of R & D systems-UK according to the manufacturer’s instructions. The concentration of sera 
bFGF in pg/ml was estimated from the standard curve. 
 
Preparation of Total Cell Extract and Western Blot Analysis: In brief, cells were scraped in 
500 µl of lysis buffer (1% triton X-100, 100 mM EDTA, 150 mM NaCl, 50 mM Tris-HCl pH 
7.4, and complete mini protease inhibitor tablets-Roche), and incubated for 15 min at 4
oC on a 
rocking platform; the cell lysates were then centrifuged at 20,800 g for 15 min at 4
oC, and the 
supernatant collected for protein quantitation using the Bradford reagent (Bio-Rad). Total cell 
extracts of the treated cells were used for analysis of APE1 and p53 proteins expression. 40 µg 
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(Trans-Blot  0.2µm;  Bio-Rad).    Signals  were  detected  after  a  1-hour  exposure  to  anti-APE1 
antibody (Santa Cruz Biotechnology).  Rabbit monoclonal anti-β-actin (Sigma) (1:1000 dilution) 
antibody  was  used  as  an  internal  control.  Followed  by  incubation  with  either  peroxidase-
conjugated  anti-mouse  or  anti-rabbit  antibody  (Sigma)  diluted  at  1:2000).  The  bands  were 
visualized according using a colorimetric detection kit. 
 
RNA extraction and RT-PCR analysis: Total RNA was extracted from cultured lymphocyts 
cells using GStractTM RNA Isolation Kit II Guanidinium Thiocyanate Method according to the 
manufacturer guidelines.  
Alterations in the APE1 and p53 levels in the treated cultured cells were determined using 
semi-quantitative  reverse  transcriptase  PCR  analysis.  Using  one-step  RT-PCR  reaction  the 
synthesized cDNA was used for amplification of target gene(s) using specific primer sets for 
APE1, F: CTG CCT GGA CTC TCT CAT CAA TAC- R: CCT CAT CGC CTA TGC CGT 
AAG and for p53, F- CAC AGT CGG ATA TGA GCA TC - R: GTC GTC CAG ATA CTC 
AGC AT.  Briefly, total RNA (1µg) and random primer (2 µg) in DEPC water were denatured at 
70 
oC for 5 min, then 10 µl of reverse transcriptase buffer, 2 µl 20 mmol/L dNTPs, 1 µl M-MLV 
reverse transcriptase (200 U) and DEPC water was added to the total volume of 20 µl. The 
reaction was performed at  42 
oC for 1 h and  at  94 
o  C for 5 min to inactivate the  reverse 
transcriptase. PCR was performed in a 25-µl reaction mixture containing 1 ml reactant, 2.5 U 
Taq DNA polymerase and 20 pmol primers, and heated for 5 min at 95 
oC for pre-denaturation, 
and then subjected to PCR cycles. PCR Products were analyzed on 2% agarose, stained with 
ethidium bromide and visualized by the UV-transilluminator.  
 
MTT  Viability  Assay:  Cell  viability  was  assessed  by  an  MTT  assay.  Lymphocytes  were 
cultured into a 24-well plate, and treated with CHOP, CHOP and curcumin or CHOP-Curcumin 
and  EGCG.  After  twelve  hours  of  incubation  the  cells  (105/well)  were  washed  twice  with 
phosphate-buffered saline (PBS), and MTT (100 µg/0.1 ml of PBS) was added to each well. The 
cells were incubated at 37
oC for four hours. The culture medium was then replaced with an equal 
volume of DMSO to dissolve formazan crystals. Absorbance was measured using a microplate 
reader at 550 nm. The cell proliferation inhibition rate was calculated as 1 - (average OD value 
of wells with administered drug/average OD value of control wells) ×100. All experiments were 
performed a minimum of three times and data was presented as the mean ± SD. 
 
GST Activity: GST activity was measured according to the method of Habig and Jakoby (26), 
using  chlorodinitrobenzene  (Sigma  Chemical)  as  substrate.  The  formation  of  GSH-
chlorodinitrobenzene conjugate was monitored by the change in absorbance at 340 nm. One unit 
of GST activity is the amount of enzyme catalyzing the conjugation of 1 μmol substrate per 
minute.  Samples  were  prepared  as  described  above  for  GSH  estimation  without  any  acid 
treatment. 
 
Statistical  Analysis:  Data  is  expressed  as  mean  values  ±  SEM.  Differences  between 
experimental groups were considered significant at a p value < 0.05 from the student’s t-test. 
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RESULTS:     
CHOP, Curcumin and EGCG combination down-regulate NF-κB, reduce sera LDH and 
β2m and modulate angiogenic factors levels: The aim of this study was to investigate the 
effect of both curcumin and EGCG on the B-cell NHL patients. Curcumin and EGCG were 
selected because they are pharmacologically safe agents that have been shown to down-regulate 
NF-κB  and  NF-κB-regulated  gene  products  involved  in  tumor  angiogenesis  and  metastasis 
including VEGF and bFGF. 
 
 
Figure 1: Changes in LDH and β2m levels in sera samples of lymphoma patients. A significant 
elevation in both LDH and β2m levels were observed in all groups of patients (I, II and III), in 
comparison  to  the  control.  A  time-dependent  reduction  in  both  LDH  and  β2m  levels  were 
observed during the treatment following the up period (three to six months). Group III of patients 
that received combination of CHOP, Curcumin and EGCG showed significant marked reduction 
compared to groups II and I. The results considered significant at p<0.05 from the control and at 
p<0.01 between the different groups.   Functional Foods in Health and Disease 2011, 1(12):525-544                                                        Page 533 of 544 
 
 
Constitutive activation of NF-κB has been reported in a wide variety of cancers including 
lymphoid  malignancies.  We  sought  to  determine  whether  curcumin  alone,  or  in  our  CHOP 
combination  suppressed  such  NF-κB  activation  in  PBMN  cells  from  Follicular  lymphoma 
patients.  
 As shown in Figure 2, the effect of Curcumin alone and in combination with EGCG was 
found to inhibit the activity of NF-κB and sensitized lymphoma patients to CHOP and induced 
remission.  
   
 
Figure 2: Results of the comparable groups in means ± SEM, constitutive active NF-κB levels 
As we can see from figures 1 and 3 the combination of curcumin with EGCG resulted in a 
synergistic antitumor activity and that with CHOP agents in additivity or sub-additivity, down-
regulated the expression of all NF-κB-regulated gene products, leading to the suppression of 
angiogenic factors VEGF and bFGF, metastasis and entering in complete remission as indicated 
by β2-microglobulin and LDH levels. Functional Foods in Health and Disease 2011, 1(12):525-544                                                        Page 534 of 544 
 
 
 
Figure 3: Time-course study of the alterations in the angiogenic factors VEGF and bFGF in sera 
samples of NHL patients.  
 
Alterations  in  the  steady-state  level  of  APE1  in  NHL  patients:  APE1  western  blotting 
analysis  indicated  marked  elevation  in  its  level  in  PMNCs  of  FL  patients  compared  to  the 
control. Representative data from four  patients is shown in figure 4. β-actin was used as an 
invariant internal control to validate the results. 
 
 
Figure 4: APE1 expression in lymph node cancer cells (Western blot). The total cell lysates are 
analyzed by Western blot. A representative samples from two controls and four patients (lanes 1 
to 4) were shown. All four tested lymphoma patients express a dominant level of APE1. Normal 
PBMC express lower level of APE1 compared with these malignant lymphoma cells. 
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Combination  of  CHOP,  Curcumin  and  EGCG  Modulate  APE1  and  p53  protein  and 
mRNA levels in cultured PBMN cells and induce cell death. To study the potential effect of 
CHOP alone or in combination with curcumin and EGCG on the APE1 and p53 protein and 
mRNA levels, PBMN cells were treated with curcumin (10 μmol/L), EGCG (100 μmol/L), or 
sequentially with both drugs for 24 hours, washed, and cultured for another 24 hours in media 
alone or with the addition of the second agent (EGCG or curcumin).  In the cells treated with 
CHOP only a marked elevation in APE1 protein and mRNA levels was observed as represented 
in figure 5. In the contrary a reduction of p53 protein and mRNA levels was observed.  An 
addition of combination to cultured cells induced reduction in APE1 both at protein and mRNA 
levels as well as an increase in p53 protein and mRNA levels as shown in figure 5.  
 
 
 
Figure 5: Western blotting and RT-PCR analyses of APE1 and p53 protein and mRNA levels in 
the cultured lymphocyte cells of 4 patients (lanes 1 to 4) collected zero time. Treatment of the 
cultured  cells  with  combination  CHOP,  curcumin  and  EGCG  for  12  hours  induced  marked 
reduction in APE1 both at protein and mRNA levels compared to the cells treated with either 
CHOP alone or CHOP and curcumin. Moreover, a marked increase in p53 protein and mRNA 
levels was observed in the same group, compared to the groups treated with CHOP alone or 
CHOP and curcumin. 
We  sought  to  determine  whether  curcumin  treatment  leads  to  cell  death  of  follicular 
lymphoma  PBMN  cells.  PBMN  cells  were  cultured  and  treated  with  CHOP,  CHOP  and 
curcumin 20 μmol/L curcumin for 24 hours, or CHOP-Curcumin and EGCG in presence of and 
cell death was determined by MTT assay. The figure shows that significant loss of cell viability 
was seen at final concentrations of 20 μmol/L curcumin treatments in combination of EGCG and 
CHOP. Curcumin at 20 μmol/L for 48 hours also caused more apoptosis in patients' PBMCs 
compared with healthy donors' PBMCs (P<0.05).  
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Figure 6: Cell viability of cultured PBMN cells. Treatment of patients’ cells with combination 
of CHOP, Curcumin (20 μmol/L) and EGCG for nine months induced significant cell death 
versus  the  mock-treated,  CHOP,  or  CHOP  and  curcumin-treated  cells.  The  reduction  in  the 
number of viable cells is significant at p < 0.05.  
 
Furthermore, plasma Glutathione S-Transferase (GST) activities were estimated to show if the 
herbal therapy could overcome the chemo-resistance of NHL-patients.  
 
Figure 7: A time-course study of the alterations in the Glutathione S-Transferase activity in sera 
samples of NHL patients. Results are expressed as means and standard deviations. Functional Foods in Health and Disease 2011, 1(12):525-544                                                        Page 537 of 544 
 
 
One of our major aims in this study was to assess the involvement of glutathione S-Transferase 
in patients through the course of treatment in the different groups. Figure 7 shows a marked 
elevation in GST activity in cancer patients receiving CHOP alone, compared to the controls. 
The addition of curcumin, EGCG improved its activity almost to a normal range within a nine 
month treatment. 
 
DISCUSSION: 
Drug resistance is a major cause of relapse and the incurability of cancer. The management of 
cancer  involves  procedures,  which  include  surgery,  radiotherapy,  and  chemotherapy. 
Development  of  chemo-resistance  is  a  persistent  problem  during  the  treatment  of  local  and 
disseminated  disease.  Gaining  a  better  insight  into  the  mechanisms  of  cancer  resistance  to 
chemotherapy might lead to new therapeutic targets and better anticancer strategies. Therapeutic 
strategies designed to increase the susceptibility of tumor cells to apoptosis have the potential to 
significantly augment the efficacy of a variety of cancer treatments.  
The  molecular  mechanisms  by  which  chemopreventive  agents  potentiate  the  antitumor 
effects of cancer therapies have not been fully elucidated. It is known that chemotherapy and 
radiotherapy can induce drug resistance in cancer cells, resulting in treatment failure. The major 
culprits involved in the development of drug resistance are the multidrug resistance gene, nuclear 
factor-κB (NF-κB), and Akt (27). We and other investigators have found that the  enhanced 
antitumor effects by chemopreventive agents could be, in part, through the regulation of NF-κB, 
Akt, and cyclooxygenase-2 (COX-2) pathways, which play important roles in cell survival (28, 
29). Combination cytotoxic chemotherapy, the treatment of choice in these cases, results in a 
modest  increase  in  survival  at  the  cost  of  significant  toxicity  to  the  patient.  This  cytotoxic 
therapy, consisting of a standard chemotherapy regimen of NHL, which is known as CHOP 
(cyclophosphamide,  doxorubicin,  vincristine,  and  prednisone),  was  added  to  turmeric  extract 
(curcumin), or to green tea extract (EGCG) (group III). This interesting polyphenolic compound 
and  EGCG  (the  predominant  and  the  major  therapeutic  agent  of  green  tea  polyphenols)  are 
endowed  with  different  molecular  targets.  In  particular,  it  has  been  frequently  reported  that 
curcumin and EGCG may interfere with NF-κB activation and increase tumor cell response to 
different  NF-κB  activating  anti-cancer  drugs,  including  doxorubicin  [30,  31].  This  is  in  full 
agreement with our results (Figure 2). 
The anti-cancer effect of curcumin has been shown, in part due to the suppression of cell 
proliferation, to cause the reduction of the tumor load and the induction of apoptosis in various 
cancer models both in vitro and in vivo [32-35]. Curcumin inhibits multiple levels within the 
transcriptional  network  to  restrict  cell  proliferation.  It  induces  p53-dependent  apoptosis  in 
various cancers of the colon, the breast, bladder, neuron, lung, ovary etc., although both p53-
dependent and -independent G2/M phase arrest by curcumin has been observed in colorectal 
cancer cells [36-39]. Curcumin arrested cell growth at the G2/M phase and induced apoptosis in 
human melanoma cells by inhibiting NFκB activation,and thus depletion of endogenous nitric 
oxide [32]. However, in mantle cell lymphoma curcumin has been found to induce G1/S arrest 
and  apoptosis  [38].  In  T  cell  leukemia  curcumin  induced  growth-arrest  and  apoptosis  in 
association with the inhibition of constitutively active Jak-Stat pathway and NFκB [39-41]. In Functional Foods in Health and Disease 2011, 1(12):525-544                                                        Page 538 of 544 
 
 
agreement with recent studies (32-41), figure 6 shows cell viability of cultured PBMN cells from 
the studied FL patients. Treatment of patients’ cells with combination of CHOP, Curcumin and 
EGCG for 9 months induced significant cell death, versus the mock-treated, CHOP, or CHOP 
and curcumin-treated cells. 
Concerning the patients treated with a combination of chemotherapy, curcumin and EGCG 
the serum levels of VEGF and bFGF were significantly higher than those of the control subjects 
before treatment. A significant reduction in both factors serum levels was observed in all patients 
receiving  the  combination  of  chemotherapy  with  the  2  natural  dietary  adjuvants  as  a  first 
response of the treatment. Our results indicate that addition of curcumin to CHOP improved the 
international prognostic indices (β2m and LDH activity), and caused a high significant decrease 
in both groups of combination therapy after six and nine months of treatment, while with green 
tea, the effect was higher than that of curcumin alone. In the other hand, the chemotherapy 
treated group did not show any significant difference in both  factors. The decrease in these 
parameters was a good prediction for complete remission (CR) rate and a well prognosis effect 
of both curcumin and green tea. We followed the patients for twelve months; eighteen of the 
patients  had  partial  remission  (PR-18/30),  and  twelve  patients  had  complete  remission  (CR- 
12/30). 
GST, which is involved in the detoxification of electrophilic toxins and carcinogens, is 
increased  in  most  of  the  human  tumors  studied.  High  concentrations  of  GST  may  rapidly 
detoxify anticancer agents, thereby preventing their cytotoxic action. Enhanced GST activity in 
follicular lymphoma samples (Figure 7) in our study supports ubiquitously-reported induction of 
GST, especially the isoenzyme GST-P in various cancer tissues and cell lines (42). Glutathione-
S-Transferase (GST) activity showed a marked increase in the chemotherapy treated group after 
nine months of treatment, and followed up to twelve  months (Figure 7), while in both curcumin 
and green tea treated group GST activity showed a significant decrease. This gives us an idea 
about the ability of both adjuvant therapies (curcumin & EGCG) to overcome the resistance of 
NHL patients to chemotherapy. This was in agreement with the recent studies, which found that 
the  inhibition  of  DNA bindings  of  both  NF-κB  and  AP-1  transcription  factors  by  curcumin 
should be responsible for a decrease in GST gene expression in malignant cells (43, 44). Green 
tea may have the same mechanism of inhibition like curcumin. 
The evaluation of hepatic and renal function during the treatment courses in all of the 
studied groups indicated the absence of any side effect of the studied adjuvant therapy (curcumin 
and green tea) in combination with chemotherapy (data not shown). Our results agree with the 
results of the recent studies. 
Overall,  prognosis  of  advanced  cancers  such  as  ovarian  cancer  (45),  hepatocellular 
carcinoma  (46),  breast,  and  lymphoma  cancer  remains  poor.  Regular  chemotherapeutic 
modalities (such as alkylating agents and CHOP compounds) and ionizing radiation used in the 
treatment of these tumors induce DNA damage (such as base damage and others) in cells. The 
proficiency of cancer cells in DNA repair makes them able to repair such DNA damage and 
continue to survive. This is a significant cause for therapeutic resistance and impacts negatively 
on  patient  outcomes.  Pharmacological  inhibition  of  DNA  repair  is  likely  to  enhance  the 
cytotoxicity in cancer cells, and improve tumor response in patients.  AP endonuclease1 (APE1), Functional Foods in Health and Disease 2011, 1(12):525-544                                                        Page 539 of 544 
 
 
is a key enzyme in the base excision repair pathway. It hydrolyzes the phosphodiester backbone 
5’ to the AP site to facilitate repair (43-44). Additionally, APE1 also functions as a redox factor, 
known as Ref-1, to reduce and activate key transcription factors such as AP-1 (Fos/Jun), p53, 
HIF-1α  and  others.  Elevated  APE1  levels  in  cancers  are  indicators  of  poor  prognosis  and 
chemotherapeutic  resistance,  and  the  removal  of  APE1  via  methodology  such  as  siRNA 
sensitizes  cancer  cell  lines  to  chemotherapeutic  agents  [45].  Our  hypothesis  is  that  a  small 
molecule inhibitor, such as curcumin of the DNA repair activity of APE1, will help elucidate the 
importance (role) of its repair function in cancer progression as wells as tumor drug response and 
will also give us a pharmacological tool to enhance cancer cells’ sensitivity to chemotherapy. 
This report is the first data demonstrating a role of a BER protein, APE1, in lymphoma patients’ 
survival and function after CHOP treatment. 
APE1/Ref-1 has been implicated in the development and progression of various cancers 
[45-49]. AP endo activity is also significantly greater in high-grade than in low-grade tumors. 
Therefore,  while  the  functional  role  of  APE1/Ref-1  in  FL  is  not  completely  understood,  a 
biological  relevance in  lymphoma seems  highly plausible.  We explored the mechanistic and 
signaling pathways that may be involved in the response of PBMCs from FL patients to CHOP 
induced stress and the role of APE1 in this process. Our objective for choosing this pathway was 
based  on  the  previously  shown  interactions  between  APE1  and  p53  in  tumor,  and  normal, 
dividing cells [13, 45, because the p53 protein plays a major role in cellular response to DNA 
damage and other genomic aberrations, particularly in mitotically growing cells. The p53 tumor 
suppressor protein is a tetrameric nuclear phosphoprotein and phosphorylation of Ser15, a key 
phosphorylation target during the p53 activation process, has been shown as being critical for 
p53-dependent transactivation [50]. DNA damage induces phosphorylation of p53 at Ser15, and 
leads to reduced interaction between p53 and its negative regulator, oncoprotein MDM2 [44, 45]. 
We investigated this pathway by performing studies using Western blot analysis and found that 
altering APE1 levels leads to alterations in the amount of p53 (Fig.5). Our results indicate an 
induction  of  p53  after  the  alteration  of  APE1  levels  and  CHOP  with  curcumin  and  EGCG 
treatment.  This  change  in  p53  was  correlated  with  modulation  of  APE1  and  implicates  this 
pathway as the primary signaling pathway involving APE1, CHOP, and ROS in PBMCs cells.  
In  conclusion,  curcumin  selectively  induces  apoptosis  in  patients’  PBMCs  compared  with 
healthy donors’ controls. These events are associated with downregulation of angiogenic factors, 
inhibition of NF-κB, decreased mRNA and protein expression of APE1 in FL cells. This is in 
total agreement with Zhang et al., 2010 (51) and our previous works (52, 53). Our findings 
provide a mechanistic rationale for the potential  use of  curcumin as  a  therapeutic agent  for 
patients with FL. 
Our study has some limitations where the observed association in FL alone may be a 
subgroup finding in Egyptian population due to chance. Therefore the finding requires validation 
in other independent cohorts. In addition, we did not evaluate the gene-environment interactions 
in lymphoma since the number of FL patients was small. However, replication of the finding 
should  be  warranted  before  proceeding  to  the  gene-environment  studies.  Also,  we  have  not 
completely  delineated  all  the  mechanisms  that  may  be  acting  with  APE1  perturbation  in 
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CONCLUSION:  
Optimal patient benefit might be obtained in follicular lymphoma when administering curcumin 
up-front in combination with chemotherapy and EGCG treatment. The combination of curcumin 
with EGCG resulted in a synergistic antitumor activity and that with CHOP agents in additivity 
or sub-additivity, down-regulated the expression of all NF-κB regulated gene products, leading 
to the suppression of angiogenesis, metastasis and entering in complete remission as indicated by 
β2-microglobulin  and  lactate  dehydrogenase  (LDH)  levels.  These  data  suggest  that  the 
combination of curcumin, EGCG and CHOP is highly effective palliative regimen for patients 
with FL with good performance status (score ≤ 3). The findings herein present prognostic and 
therapeutic  implications  for  treating  follicular  lymphoma.  The  APE1-inhibition  results 
demonstrate the feasibility of the therapeutic modulation of APE1 using a variety of molecules 
and approaches. This report is the first data demonstrating a role of a BER protein, APE1, in 
lymphoma  patients’  survival  and  function  after  CHOP  treatment.  These  results  show  that 
addition of curcumin and EGCG to CHOP achieved long-lasting remissions in 18 of 30 (60%) 
FL lymphoma patients in relapse after 1 or multiple chemotherapies 
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